|Other Names||Melanoma-associated antigen B2, Cancer/testis antigen 32, CT32, DSS-AHC critical interval MAGE superfamily 6, DAM6, MAGE XP-2 antigen, MAGE-B2 antigen, MAGEB2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6172a was selected from the N-term region of human MAGEB2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex.|
|Tissue Location||Expressed in testis and placenta, and in a significant fraction of tumors of various histologic types|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MAGEB2 is a member of the MAGEB gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 68% sequence identity to each other. The promoters and first exons of the MAGEB genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. This gene is localized in the DSS (dosage-sensitive sex reversal) critical region. It is expressed in testis and placenta, and in a significant fraction of tumors of various histological types. The MAGEB genes are clustered on chromosome Xp22-p21.
Park, J.H., et al., Mol. Cells 13(2):288-295 (2002).Lurquin, C., et al., Genomics 46(3):397-408 (1997).Dabovic, B., et al., Mamm. Genome 6(9):571-580 (1995).
If you have any additional inquiries please email technical services at email@example.com.